Urticaria  >>  Ruconest (conestat alfa)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ruconest (conestat alfa) / SOBI, Pharming Group
NCT00262301 / 2005-000206-31: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Completed
3
75
Europe
recombinant human C1 inhibitor, "rhC1INH", Ruconest, conestat alfa, Placebo, saline, physiological salt solution
Pharming Technologies B.V.
Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders
07/09
10/09
NCT00225147: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Completed
2/3
77
Europe
Recombinant Human C1 Inhibitor, "rhC1INH", Ruconest, conestat alfa, placebo, saline, physiological salt solution
Pharming Technologies B.V.
Hereditary Angioedema, Angioneurotic Edema
10/09
01/10

Download Options